Article Text

other Versions

CSF oligoclonal band status informs prognosis in MS: a case control study of 100 patients
  1. Fady G Joseph (fadygjoseph{at}
  1. Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, United Kingdom
    1. Claire L Hirst (clairehirst_uk{at}
    1. University Hospital of Wales, United Kingdom
      1. Trevor Pickersgill (trevor.pickersgill{at}
      1. University Hospital of Wales, United Kingdom
        1. Yoav Ben-Shlomo (y.ben-shlomo{at}
        1. University of Bristol, United Kingdom
          1. Neil P Robertson (robertsonnp{at}
          1. UWCM, United Kingdom
            1. N J Scolding (n.j.scolding{at}
            1. University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, United Kingdom


              Objective: Oligoclonal band (OCB)-negative MS is well-recognised but uncommon, studied in only a few, usually small case series. These reach differing conclusions on whether its clinical features or course differ from OCB-positive disease. We hypothesised that a definitive study would not only be of clinical and prognostic value but also potentially offer information about the possible role of CSF oligoclonal immunoglobulins in MS disease processes.

              Methods: We utilised a collaborative cohort of well-documented patients in southwest England and south Wales to identify and analyse a large group of patients with OCB-negative MS and make comparisons with age- and sex-matched OCB-positive controls.

              Results: An approximate minimum 3% of patients with MS were OCB-negative. They were significantly more likely to exhibit neurological or systemic clinical features atypical for MS (headaches, neuropsychiatric features and skin changes). Non-specific MRI, blood and (other) CSF abnormalities were also more common, emphasising the need for continued diagnostic vigilance – although the incautious application of McDonald diagnostic criteria in OCB-negative cases renders categorisation as “definite” MS more likely. Studying the uniformly-assessed Cardiff group (69 patients), we found the prognosis for neurological disability was significantly better for OCB-negative cases. The age-adjusted hazard-ratio for OCB-negative and OCB-positive subjects to reach DSS4 and DSS6 was respectively 0.60 (95% CI 0.39-0.93, p=0.02) and 0.51 (95% CI 0.27-0.94, p=0.03).

              Interpretation: There are clear clinical differences between OCB-negative and OCB-positive MS, in particular a better prognosis for disability. This is consistent with a secondary but nonetheless contributory role in disease process for intrathecally-synthesised immunoglobulins.

              Statistics from

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.